4/13/2012

Bayer is seeking EU authorization to market anti-coagulant rivaroxaban as a pulmonary embolism therapy. Partner Johnson & Johnson will apply this quarter for FDA approval of rivaroxaban to treat venous thromboembolism, a Bayer spokeswoman said.

Full Story:
Fox Business

Related Summaries